SAKIS: Stockholm Acute Kidney Injury Cohort
Study Details
Study Description
Brief Summary
Since 2009, adult patients with acute kindney injury (AKI) at the department of Nephrology, Danderyd University Hospital and Karolinska Institutet, have been included in a prospective cohort. All patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively.
By 2020, 1861 patiens have been included of which 1519 fulfill current AKI criteria (as defined by KDIGO AKI guidelines) and will be evaluated regarding the following main research questions:
-
Descriptive study on patient characteristics, changes in biomarkers and in-hospital outcome.
-
One year outcome with focus on renal and cardiovascular outcomes.
-
Long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Acure kidney injury (AKI) remains a complex clinical challenge associated with high risk for short-term and long-term adverse events. Since 2009 patients with AKI at the department of Nephrology, Danderyd University Hospital and Karolinska Institutet, have been included in a prospective cohort. Adult patients with either s-creatinine >130 micromol/L and previously unknown level, or 30% increase from previous known level were included; patients on dialysis were not included. All patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively.
By 2020, 1861 patiens have been included of which 1519 fulfill current AKI criteria and will be evaluated regarding the following main research questions:
-
Descriptive study on in-hospital outcome (death, renal recovery), patient characteristics, hyperkalemia and changes in biomarkers reflecting inflammation, acidosis and malnutrition.
-
One year outcome with focus on renal and cardiovascular outcomes (death, new dialysis, worsened renal function, myocardial infarction, stroke, or heart failure; MARCE).
-
Long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes (MARCE).
Study Design
Outcome Measures
Primary Outcome Measures
- In-hospital outcome [From admission until discharge or death, assessed for a period of up to 3 months]
Death
- 1-year outcome [From admission until 1 year]
Descriptive study on Major Adverse Renal or Cardiovascular Events (death, new dialysis, worsened renal function, myocardial infarction, stroke, or heart failure; MARCE)
- Long-term outcome [From admission until 10 years]
Descriptive study on Major Adverse Renal or Cardiovascular Events (MARCE)
Secondary Outcome Measures
- In-hospital partial renal recovery [From admission until discharge or death, assessed for a period of up to 3 months]
Renal recovery by 30% at the time of discharge or death
- In-hospital renal recovery [From admission until discharge or death, assessed for a period of up to 3 months]
Renal recovery by 50% at the time of discharge or death
- In-hospital biomarkers [From previous values or values at admission until discharge or death, assessed for a period of up to 3 months]
Changes in biomarkers with focus on potassium, malnutrition, inflammation and acidosis
Eligibility Criteria
Criteria
Inclusion Criteria (one of the following):
-
Serum creatinine (sCr) >130 µmol/l (1.47 mg/dl) at admission with previously unknown baseline,
-
Increase in sCr by 30% from previous stable out-patient value.
Exclusion Criteria:
Ongoing dialysis treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Karolinska Institute at Danderyd University Hospital | Danderyd | Stockholm | Sweden | 18288 |
| 2 | Danderyd University Hospital | Stockholm | Sweden | 18288 |
Sponsors and Collaborators
- Danderyd Hospital
Investigators
- Study Director: Christina Montgomerie, MD, Karolinska Institutet and Danderyd University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SAKIS